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ABSTRACT 1 
Background: Outcomes of liver resection for hepatocellular carcinoma (HCC) have 2 
improved due to better surgical techniques and patient selection. Portal hypertension 3 
may influence outcome but the preoperative definition and role of portal hypertension 4 
are far from clear. The aim of this study was to elucidate the influence of intraoperative 5 
directly measured portal venous pressure (PVP) on outcomes of liver resection in 6 
patients with HCC. 7 
Methods: Patients who underwent resection of their HCC between 1997 and 2009 and 8 
who underwent direct measurement of PVP immediately after laparotomy were enrolled. 9 
These patients were divided into two groups according to PVP; PVP≥ 20 cmH2O (high 10 
PVP group) or PVP < 20 cmH2O (low PVP group). The influence of PVP on survival 11 
rates and recurrence free survival rates was analyzed and prognostic factors were 12 
identified.  13 
Results: A total of 177 patients were enrolled, 129 in low PVP group and 48 in high 14 
PVP group. The 5-year survival rate and recurrence free survival rate were significantly 15 
higher in patients with low PVP 63.7% vs. 31.4%, (P < 0.001) and 52.5% vs. 12.1% (P 16 
< 0.001), respectively. In multivariate analysis, tumor number ≥2, tumor diameter ≥5cm, 17 
high PVP, liver damage of class B, hepatic activity index (HAI) grading ≥7 and AFP 18 
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≥100 ng/ml were significant predictors of poorer survival after liver resection. Tumor 1 
number ≥2, tumor diameter ≥ 5cm and HAI grading ≥7 were significant predictors of a 2 
poorer recurrence.  3 
Conclusion: Portal venous pressure is associated with the long term outcome of liver 4 
resection for HCC. 5 
6 
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INTRODUCTION 1 
Hepatocellular carcinoma (HCC) is one of the most common malignancies 2 
worldwide (1). Outcomes of liver resection for HCC have improved significantly in 3 
recent years because of improved surgical techniques and better perioperative 4 
management (2, 3). Adequate estimation of preoperative liver function and tailoring the 5 
extent of hepatectomy based on liver function have reduced postoperative mortality and 6 
morbidity rates (2-4).  7 
The degree of portal hypertension probably reflects the severity of liver fibrosis 8 
in patients with liver cirrhosis (LC). Patients with LC often have portal hypertension 9 
preoperatively, and currently are not candidates for liver resection, especially major 10 
hepatectomy, according to USA and European guidelines (5, 6). Several reports have 11 
shown that the preoperatively estimated portal hypertension was associated with the 12 
prognosis of HCC (7, 8). Major hepatic resection increases portal venous pressure 13 
(PVP) in cirrhotic and non-cirrhotic livers, this increase in PVP after hepatectomy 14 
however does not seem to have a direct effect on early postoperative morbidity and 15 
mortality (10). On the other hand, directly measured high PVP during hepatectomy was 16 
associated with complications after hepatectomy in cirrhotic patients with HCC (11).  17 
The aim of the present study was to clarify whether PVP reflects prognosis of 18 
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patients with HCC after hepatic resection and to identify factors affecting recurrence 1 




 All patients with HCC, who underwent curative hepatic resection between 6 
January 1997 and December 2009 in the Department of Surgery, Nagasaki University 7 
Hospital and in whom PVP was measured were eligible for the study. Curative resection 8 
was defined as an operation in which all tumors were macroscopically resected during 9 
surgery. Hepatic resection was performed based on preoperative tumor staging and liver 10 
function tests. The selection for minor resection (partial hepatectomy or 11 
segmentectomy) or major resection (bisegmentectomy and lobectomy) was based on the 12 
location and diameter of HCC and liver function test (10).  Tumor staging included 13 
preoperative ultrasonography (US), multidetector computed tomography (MDCT), and 14 
magnetic resonance imaging (MRI) in all patients. Preoperative liver function was 15 
assessed by liver function tests, indocyanine green retention for 15 minutes (ICG-R15), 16 
liver scintigraphy represented by liver to liver plus heart ratio at 15 minutes after 99mTc 17 
Galactosyl sialyl albumin (GSA) loading (LHL15) and Child-Pugh classification. 18 
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Patient data collected before surgery included age, sex, virus status, platelet count 1 
(x104/mm3), prothrombin time (PT) (%), albumin (g/dL), total bilirubin (mg/dL), 2 
alanine aminotransferase(ALT) (IU/L), Child-Pugh class, liver damage defined by Liver 3 
Cancer Study Group of Japan (LCSGJ)(12), ICG R15 and LHL15. 4 
Intra-operative PVP measurement was performed as described previously (10, 5 
11). Briefly, a catheter was inserted into a jejunal mesenteric vein around 100cm to 6 
120cm from Treitz’s ligament before liver mobilization and resection. PVP was then 7 
measured using a water pressure gauge with saline. Patients with a history of upper 8 
abdominal surgery and mesenteric membrane adhesions were excluded because 9 
intubation could not be done easily after laparotomy. A high PVP was defined as 10 
pressure ≥ 20 cmH2O (10, 11). Pressure over 15 mmHg was considered an indicator to 11 
avoid small for size graft syndrome after liver transplantation. Generally, A PVP of 15 12 
mmHg was taken to be equal to 20 cmH2O (conversion factor 1.36) (13). Patients were 13 
divided a high PVP group (≥ 20.0 cm H2O) and a low PVP group (< 20.0 cmH2O) at the 14 
time of the operation. Liver dysfunction was defined as patients with hyper 15 
bilirubinemia, severe ascites, lower prothrombin time, and elevated sustained liver 16 
functional test after hepatectomy. 17 
Postoperative follow up included serum alpha-fetoprotein (AFP) and serum 18 
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protein induced by vitamin K absence II (PIVKA-II) levels, and US, CT or MRI every 2 1 
or 3 months. If indicated, chest CT or bone scintigraphy were performed. If tumor 2 
recurrence was found, the optimal treatment (transarterial chemoembolization for 3 
intrahepatic multiple recurrence, radio frequency ablation for single small recurrence, 4 
repeat hepatectomy for single intrahepatic recurrence) was selected for patients with 5 
preserved liver function. 6 
 7 
Analyses and Statistics 8 
 Preoperative clinical data in the high PVP and low PVP groups were compared 9 
including age, sex, virus status, Child-Pugh classification, liver damages, ICG R15, 10 
LHL15, platelet count (x104/mm3), prothrombin time (%), serum albumin (g/dL), total 11 
bilirubin (mg/dL), alanine aminotransferase (IU/L), AFP (ng/ml), PIVKA-II (mAU/ml) 12 
and pathological data including tumor number and diameter, vascular invasion, liver 13 
inflammation and fibrosis using the hepatic activity index (HAI) (14). Clinical and 14 
pathological factors related to the presence of high PVP were compared by 15 
Mann-Whitney U test and Chi square test. Survival was analyzed from day of surgery to 16 
most recent follow-up. Recurrence after surgery was determined by the image study. 17 
Survival and recurrence free survival rates between high PVP and low PVP were 18 
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assessed with the Kaplan-Meier method using the log-rank test. To clarify the 1 
prognostic factors for survival and recurrence, 14 clinical and pathological variables 2 
were determined. Factors on liver function included platelet count, Child-Pugh 3 
classification, liver damage, ICG R15. Tumor factors included AFP level, PIVKAII 4 
levels, maximum tumor size, number of tumor, type of resection, vascular invasion, 5 
HAI grading and staging. Univariate and multivariable analyses of prognostic factors 6 
were performed using the Cox proportional hazard model. Differences were considered 7 
statistically significant when the p-values were < 0.05. Statistical analyses were done 8 
using SPSS Version 18.0 software package (Tokyo, Japan). 9 
 10 
RESULTS 11 
Patient characteristics and differences between high and low PVP 12 
Eighty-three percent of patients were male, and median age was 65 (20–81). 13 
Forty-seven patients (26.6%) were seropositive for hepatitis B antigen (HBs-Ag), three 14 
(1.7%) were seropositive HBs-Ag and hepatitis C antibody (HCV-Ab), 84 (47.4%) were 15 
seropositive for HCV and 43 (24.3%) were seronegative for both HBs-Ag and HCV-Ab. 16 
There were 48 patients with high PVP and 129 patients with low PVP. The 17 
characteristics of patients with high PVP and low PVP, which was assessed along with 18 
HIDAKA et al.  
 10 
the parameters related to the PVP, are described in Table 1. Patients with a high PVP 1 
had a lower platelet count, a lower PT, lower albumin, higher ALT, higher CP class, 2 
higher liver damage class, higher ICG R15, lower LHL15, higher AFP level, and less 3 
frequent solitary tumors, resulting in fewer major hepatectomies, and a higher hepatic 4 
activity index (HAI) grading and staging. Eighteen patients had less than 10x104/mm3 5 
platelets in the high PVP group (27.1%) and 13 (10%) in the low PVP group. Twenty 6 
patients (41.6%) in the high PVP group developed complications after hepatectomy, 7 
including ascites in 8 (16.6%), pleural effusion in 8 (16.6%), and infectious disease in 8 8 
(16.6%) patients. Fifty-four patients (41.9%) with low PVP developed complications, 9 
with ascites in 18 (13.9%), pleural effusion in 23 (17.8%), and infectious disease in 9 10 
(7%) respectively. There were no differences in postoperative incidence of the pleural 11 
effusion, ascites, and infection between the high and low PVP groups. However, 12 
patients with a high PVP had significantly more often liver dysfunction (n=7) compared 13 
to the low PVP group (n=2, p=0.01).  14 
 15 
Patient survival and recurrence free survival 16 
 Median follow-up of all patients was 39.2 months (1.1-207). Five patients died 17 
due to liver failure and sepsis with multi-organ failure after hepatectomy. Recurrence 18 
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after resection developed in 37 patients (77.0%) in the high PVP group, and in 93 1 
patients (72.1%) in the low PVP group. The one, 3- and 5-year survival rates of the 2 
low PVP group (n=129) were 92.0%, 78.2% and 63.7%, respectively. This was 3 
significantly better than the corresponding 72.9%, 48.5% and 31.4% survival rates in 4 
the high PVP group (n=48) (p < 0.001) Figure 1. The 1-year, 3-year and 5-year 5 
recurrence free survival rates of the low PVP group were 73.9%, 61.0% and 52.5%, 6 
respectively. This again was significantly better than the corresponding 47.7%, 27.0% 7 
and 12.1%, respectively in the high PVP group (p < 0.001) Figure 2. 8 
 9 
Prognostic factors for survival and recurrence free survival 10 
 Univariate analysis identified 7 significant prognostic factors for survival in 11 
patients with high PVP. The presence of multiple tumors, tumor diameter ≥ 5cm, high 12 
PVP, liver damage class B, HAI grading ≥ 7, AFP ≥100 ng/ml, and vascular invasion 13 
were significant prognostic factors for poorer survival (Table 2). 14 
A multivariable analysis was performed for survival based on the variables 15 
identified as significant in the univariate analysis. Presence of multiple tumors, tumor 16 
diameter ≥ 5cm, high PVP, liver damage, and a HAI grading ≥ 7 were identified as 17 
independent prognostic indicators for survival.  18 
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 Table 3 shows the results of the univariate analysis to identify factors related to 1 
recurrence. Poor prognostic factors were the presence of multiple tumors, tumor 2 
diameter ≥ 5cm, an HAI grading ≥ 7, high PVP, vascular invasion, and AFP ≥ 100ng/ml. 3 
The presence of multiple tumors, tumor diameter ≥ 5cm, and an HAI grading ≥ 7 were 4 




 Portal hypertension is considered to be a contraindication for liver resection 9 
according the EASL/AASLD guidelines (5, 6). However, in recent years liver resection 10 
for cirrhotic patients has been performed safely. According to these guideline, treatment 11 
for such patients with HCC should be local therapy, such as radio frequency ablation 12 
(RFA) or transarterial chemoembolization (TACE). Bruix et al. reported that a hepatic 13 
venous pressure gradient ≥10 mmHg was the most powerful predictor of postoperative 14 
liver failure in cirrhotic patients (7). Caupussoti et al. observed that survival was worse 15 
in patients with portal hypertension than in patients without portal hypertension, 16 
although the results were similar for patients with or without portal hypertension if only 17 
patients with Child-Pugh A disease were evaluated (9).  On the other hand, Imamura et 18 
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al. analyzed 1056 consecutive liver resections (532 for HCC, 262 for other liver 1 
malignancies, 57 for biliary tract malignancy, 174 living donor and 31 for other disease) 2 
that did not result in mortality over a period of 8 years. They concluded that portal 3 
hypertension and liver cirrhosis did not affect overall postoperative complications in 4 
patients with HCC, and identified blood loss greater than or equal to 1000 mL as the 5 
major risk factor (3).  6 
Cucchetti et al. performed a retrospective one-to-one matched analysis of 241 7 
cirrhotic patients divided in 2 groups according to the presence or absence of portal 8 
hypertension. They identified the preoperative MELD score as the major determinant of 9 
postoperative outcome. Portal hypertension in this analysis did not affect postoperative 10 
complication rates in patients with HCC (15).  11 
The present study demonstrated that a high PVP is related to of liver 12 
inflammation and fibrosis as evidenced by the incidence of lower platelets, PT, albumin, 13 
a higher Child Pugh score, HAI grading and staging. Partial hepatectomies or 14 
segmentectomies, i.e. limited hepatic resections of the liver, were deemed appropriate 15 
more often for patients with a high PVP as patients with a PVP ≥ 20 cm H2O are more 16 
likely to develop hyperbilirubinemia after hepatectomy (11). Limited resections for 17 
patients with liver cirrhosis proved to be an effective treatment for HCC to avoid liver 18 
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dysfunction and mortality after hepatectomy in the author’s unit (16).  1 
HCC in patients with severe cirrhosis can arise anywhere in the cirrhotic liver 2 
as multicentric occurrence carcinogenesis. Minute and ‘undetectable’ HCC may be 3 
found in explant livers in patients with severe cirrhosis at liver transplantation (17).  4 
The differences between the present data and those of other reports may have resulted 5 
from the cut-off values of PVP that were used in the different studies. The BCLC group 6 
labeled patients as having hypertension based on the presence of esophageal varices, 7 
splenomegaly and a platelet count < 100,000/mm3. This differs markedly from the direct 8 
measurement of portal vein pressure during surgery (7). Figueras reported that portal 9 
vein pressure at the beginning of surgery, hepatic venous pressure gradient (HVPG), 10 
high central venous pressure (CVP), and intraoperative blood loss were factors 11 
associated with complications after liver resection (18). In the current authors’ 12 
indication CVP before liver resection was usually 5 mmHg, and it was assumed that a 13 
PVP of 20cmH2O before liver resection would be equivalent to a PVP of 15mmHg and 14 
an HVPG of 10mmHg (HVPG = PVP – CVP). However detailed data concerning the 15 
CVP at the start of surgery in this study were not available.  16 
 Capussotti et al. showed that the presence of portal hypertension in patients 17 
with Child Pugh-A did not affect overall survival (9). Ripoll et al. showed that portal 18 
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hypertension, assessed via a hepatic venous pressure gradient, was an independent 1 
predictor of survival of patients (8). The present data support these results indicating 2 
that overall survival and recurrence free survival rates after hepatectomy were worse in 3 
patients with high PVP (assessed by direct portal venous pressure) > 20 cm H2O. In this 4 
study, overall survival was lower in patients with high PVP because of their worse liver 5 
function. A high PVP may reflect inflammation and fibrosis in the liver, and may be 6 
associated with liver dysfunction because HAI grading of the background liver and 7 
staging was worse in the high PVP group than in the low PVP group. A multivariable 8 
analysis for recurrence revealed that the presence of multiple and huge tumors, and 9 
inflammation in the remnant liver, were associated with earlier recurrence of HCC after 10 
hepatectomy even after curative resection. Indeed high PVP was not associated with 11 
recurrence although RFS in high PVP group was significantly inferior to that in the low 12 
PVP group. High PVP was the fourth harvest associated with recurrence followed by 13 
high HAI Grading. High PVP may have the potential inflammation in the remnant liver 14 
and reflect the impaired liver function which caused to the potential multi-centric 15 
carcinogenesis in the liver. 16 
 HPVG measurement allows selection of patients pre-operatively and therefore, 17 
this may be more appropriate in the future. 18 
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Figure legends 1 
Figure 1. Comparison of survival in patients with an HCC and high PVP or low PVP 2 
after hepatectomy (p < 0.001). PVP, portal venous pressure  3 
 4 
Figure 2. Comparison of the recurrence free survival in  patients with an HCC and 5 
high PVP or low PVP after hepatectomy (p < 0.001). PVP, portal venous pressure 6 
 7 
Table 1. Clinical characteristics of patients with high or low PVP under going 8 
hepatectomy for HCC  9 
AFP, alpha-fetoprotein; ALT, alanine aminotransferase; HAI, hepatic activity index; 10 
ICG R15, indocyanine green retention test at 15 minutes; LHL, liver to liver plus heart 11 
uptake ratio at 15 minutes; PIVKA II, protein induced by vitamin K absence II. 12 
 13 
Table 2. Results of univariate and multivariable analyses of prognostic factors  14 
regarding survival after hepatectomy 15 
AFP, alpha-fetoprotein; ICG R15, indocyanine green retention test at 15 minutes; LHL, 16 
liver to liver plus heart uptake ratio at 15 minutes; PIVKA II, protein induced by 17 
vitamin K absence II; PVP, portal venous pressure. 18 
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 1 
Table 3. Results of the univariate and multivariable analyses of prognostic factors  2 
regarding recurrence after hepatectomy 3 
AFP, alpha-fetoprotein; ICG R15, indocyanine green retention test at 15 minutes; LHL, 4 
liver to liver plus heart uptake ratio at 15 minutes; PIVKA II, protein induced by 5 




Table 1. Clinical characteristics of patients with high or low PVP  




(n = 48) 
Low PVP 
(< 20 cmH2O) 
(n = 129) p-value 
Ages (years) 63 (43 - 78) 66 (20 - 81) 0.162 
Sex (M : F) 40  :  8 107  :  22 0.856 
Etiology 0.347 
    Hepatitis B 14 (29.2%) 33 (25.6%) 
    Hepatitis C 26 (54.2%) 58 (45.0%) 
    Hepatitis B + C 1 (2.0%) 2 (1.5%) 
    Negative 7 (14.6%) 36 (27.9%) 
Platelet count (x104/mm3) 11.8 (4.1 - 35.6) 15.9 (2.6 - 47) 0.001 
Prothrombin time (%) 83.7 (63 - 105) 91 (54 - 122) 0.002 
Albumin (g/dl) 3.8 (2.5 - 4.7) 4.0 (2.8 - 4.8) 0.001 
Total bilirubin (mg/dl) 0.9 (0.4 - 4.8) 0.7 (0.3 - 2.4) 0.06 
ALT (IU/L) 55.5 (18 - 190) 34.5 (7 - 222) 0.002 
Child Pugh classification 0.004 
    Class A 38 (79.2%) 122 (94.6%) 
    Class B 10 (20.8%) 7 (5.4%) 
Liver damage 0.001 
    Class A 30 (62.5%) 109 (76.8%) 
    Class B 18 (37.5%) 17 (13.2%) 
ICG R15 (%) 18 (3 - 39) 11 (1 - 40) 0.004 
LHL15 0.89 (0.77 - 0.96) 0.93 (0.61 - 0.97) 0.001 
AFP (ng/ml) 47.5 (4.2 - 454,300) 13.1 (1.2 - 151,367) 0.03 
PIVKAII (mAU/ml) 73 (21 - 10,173) 133 (2 - 60,380) 0.52 
Tumor diameter (cm) 2.9 (1.0 - 13.0) 4.0 (0.5 - 17.0) 0.08 
Solitary tumor 29 (59.1%) 101 (78.3%) 0.01 
Type of hepatectomy 
    Minor hepatectomy 41 (85.4%) 76 (58.9%) 0.001 
    Major hepatectomy 7 (14.6%) 53 (31.1%) 
Vascular invasion 10 (26.3%)  40 (31.9%) 0.207 
HAI 
    Grading 9.1 (3 - 13) 4.8 (1 - 13) 0.001 
    Staging 3.8 (2 - 4) 2.1 (0 - 4) 0.001 
 
 
Univariate analysis   
 
Multivariable analysis   
Variables Category Hazard ratio 95% CI p-value   Hazard ratio 95% CI p-value 
Tumor number ≥ 2  3.15 2.02 - 4.90 <0.001 
 
2.52 1.58 - 4.02 <0.001 
Tumor diameter (cm) ≥ 5 1.67 1.09 - 2.54 0.018 
 
2.22 1.41 - 3.50 0.001 
PVP ≥ 20cmH2O 2.44 1.60 - 3.60 <0.001 
 
1.74 1.24 - 3.03 0.004 
Liver damage B 1.91 1.19 - 3.07 0.007 
 
1.74 1.07 - 2.82 0.026 
HAI Grading ≥ 7 2.14 1.42 - 3.25 <0.001 
 
1.65 1.04 - 2.63 0.034 
AFP (ng/ml) ≥ 100 1.69 1.11 - 2.57 0.013 
   
0.354 
Vascular invasion + 1.68 1.08 - 2.61 0.02 
   
0.521 
Platelet count (x104/mm3) ≤ 10 0.99 0.60 - 1.63 0.985 
    
ICG R15 (%) ≥ 15 1.21 0.81 - 1.80 0.354 
    
LHL 15 ≤ 0.9 0.6 0.34 - 1.07 0.79 
    
PIVKA II ≥ 100 0.85 0.53 - 1.37 0.515 
    
Child Pugh B 1.49 0.83 - 2.70 0.177 
    
Partial hepatectomy + 1.17 0.77 - 1.76 0.465 
    
HAI Staging 4 1.31 0.84 - 2.03 0.24         
 
Table 2. Results of univariate and multivariable analyses of prognostic factors regarding survival after hepatectomy 
 
AFP, alpha-fetoprotein; HAI, hepatic activity index; ICG R15, indocyanine green retention test at 15 minutes; LHL, liver to liver plus heart uptake 












Univariate analysis   
 
Multivariable analysis   
Variables Category Hazard ratio 95% CI p-value  Hazard ratio 95% CI p-value 
Tumor number ≥  2  2.49 1.68 - 3.69 <0.001 
 
2.3 1.49 - 3.54 <0.001 
Tumor diameter (cm) ≥  5 1.86 1.27 - 2.72 0.001 
 
2.19 1.39 - 3.17 <0.001 
HAI Grading ≥  7 1.77 1.21 - 2.57 0.003 
 
1.72 1.16 - 2.56 0.007 
PVP ≥  20cmH2O 1.65 1.10 - 2.48 0.014 
   
0.328 
Vascular invasion + 1.65 1.10 - 2.48 0.015 
   
0.479 
AFP (ng/ml) ≥ 100 1.49 1.01 - 2.23 0.047 
   
0.189 
Platelet  count (x104/mm3) ≤ 10 1.04 0.66 - 1.65 0.854 
    ICG R15 (%) ≥ 15 1.3 0.94 - 1.96 0.1 
    LHL 15 ≤ 0.9 0.74 0.48 - 1.17 0.195 
    PIVKA II ≥  100 1.39 0.95 - 2.03 0.085 
    
Child Pugh B 1.09 0.60 - 1.98 0.775 
    Liver damage B 1.36 0.87 - 2.13 0.167 
    Partial hepatectomy + 1.08 0.74 - 1.57 0.704 
    HAI Staging 4 1.01 0.66 - 1.55 0.957     
 
Table 3. Results of the univariate and multivariable analyses of prognostic factors regarding recurrence after hepatectomy 
 
AFP, alpha-fetoprotein; HAI, hepatic activity index; ICG R15, indocyanine green retention test at 15 minutes; LHL, liver to liver plus heart uptake 
ratio at 15 minutes; PIVKA II, protein induced by vitamin K absence II; PVP, portal venous pressure.  
 
